A new and highly anticipated study by Celgene Corp. (NASDAQ: CELG) shows that its promising multiple sclerosis drug could soon reshape the $19 billion multiple sclerosis market. On Friday, management reported that ozanimod met its primary endpoint for reducing MS relapses better than Biogen Inc.’s (NASDAQ: BIIB) Avonex, and importantly, it did so without any new safety risks.